Evaluating the effect of immune cells on the outcome of patients with mesothelioma.

Evaluating the effect of immune cells on the outcome of patients with mesothelioma.
复制标题

DOI:
10.1038/bjc.2017.269
复制
发表时间:
2017-10-24
影响因子:
8.8
通讯作者:
Ottensmeier CH
Ottensmeier CH
中科院分区:
医学1区
文献类型:
--
作者:
Chee SJ;Lopez M;Mellows T;Gankande S;Moutasim KA;Harris S;Clarke J;Vijayanand P;Thomas GJ;Ottensmeier CH

文献摘要

参考文献

被引文献

相似文献

我们系统地评估了一个大型的晚期间皮瘤患者队列中浸润的适应性和先天免疫细胞的预后和预测价值。从302个样本中构建了组织芯片。评价了T细胞(CD 8+、FOXP 3+、CD 4+、CD 45 RO+、CD 3+)和B细胞(CD 20+)中的适应性免疫应答标志物,以及先天性免疫应答标志物;中性粒细胞(NP 57+)、自然杀伤细胞(CD 56+)和巨噬细胞(CD 68+)。我们发现,在上皮样肿瘤中,高CD 4+和CD 20+计数,低FOXP 3+,CD 68+和NP 57+计数与更好的结果相关。在非上皮样细胞组中,低CD 8+和低FOXP 3+计数是有益的。在多变量分析中,低FOXP 3+仍然与两组的生存独立相关。在上皮样组中,另外高CD 4+、高CD 20+和低NP 57+计数是预后的。我们的数据第一次证明,在主要是晚期疾病中,适应性和先天免疫的关键标志物与生存率和组织学差异的相关性。更好地了解间皮瘤不同亚型的免疫驱动因素将有助于诊断和疾病特异性临床决策。
We systematically assessed the prognostic and predictive value of infiltrating adaptive and innate immune cells in a large cohort of patients with advanced mesothelioma. A tissue microarray from 302 samples was constructed. Markers of adaptive immune response in T-cells (CD8+, FOXP3+, CD4+, CD45RO+, CD3+) and B-cells (CD20+), and of innate immune response; neutrophils (NP57+), natural killer cells (CD56+) and macrophages (CD68+) were evaluated. We found that in the epithelioid tumours, high CD4+ and CD20+ counts, and low FOXP3+, CD68+ and NP57+ counts linked to better outcome. In the non-epithelioid group low CD8+ and low FOXP3+ counts were beneficial. On multivariate analysis low FOXP3+ remained independently associated with survival in both groups. In the epithelioid group additionally high CD4+, high CD20+, and low NP57+ counts were prognostic. Our data demonstrate for the first time, in predominately advanced disease, the association of key markers of adaptive and innate immunity with survival and the differential effect of histology. A better understanding of the immunological drivers of the different subtypes of mesothelioma will assist prognostication and disease-specific clinical decision-making.
DOI: 10.1016/j.ccr.2012.02.022
发表时间: 2012-03-20
期刊: CANCER CELL
影响因子: 50.3
作者:
Hanahan, Douglas;Coussens, Lisa M.
通讯作者: Coussens, Lisa M.
DOI: 10.1158/1078-0432.ccr-05-1886
发表时间: 2006-01-15
影响因子: 11.5
作者:
Badoual, C;Hans, S;Tartour, E
通讯作者: Tartour, E
DOI: 10.1007/s00262-003-0388-5
发表时间: 2003-07-01
影响因子: 5.8
作者:
Diederichsen, ACP;Hjelmborg, JV;Fenger, C
通讯作者: Fenger, C
DOI: 10.1186/s12967-014-0301-3
发表时间: 2014-12-04
影响因子: 7.4
作者:
Comertpay, Sabahattin;Pastorino, Sandra;Carbone, Michele
通讯作者: Carbone, Michele
DOI: 10.1016/j.immuni.2014.06.010
发表时间: 2014-07-17
期刊: IMMUNITY
影响因子: 32.4
作者:
Noy, Roy;Pollard, Jeffrey W.
通讯作者: Pollard, Jeffrey W.